Dissociation Between the Potent β-Amyloid Protein Pathway Inhibition and Cholinergic Actions of the Alzheimer Drug Candidates Phenserine and Cymserine

Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353–356.PubMedCrossRefGoogle Scholar

Sambamurti K, Greig NH, Lahiri DK. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromol Med (2002;1:1–31.CrossRefGoogle Scholar

Lahiri DK, Farlow MR, Greig NH, et al. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 2003;4(2):97–112.PubMedCrossRefGoogle Scholar

Sambamurti K, Granholm AC, Kindy MS, et al. Cholesterol and Alzheimer’s disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets 2004;5(6):517–528.PubMedCrossRefGoogle Scholar

Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003;11(2):131–145.PubMedCrossRefGoogle Scholar

DeKosky ST. Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J Am Geriatr Soc 2003;51(5 Suppl Dementia):S314–S320.PubMedCrossRefGoogle Scholar

Lahiri DK, Rogers JT, Greig NH, Sambamurti K. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des 2004;10(25):3111–3119.PubMedCrossRefGoogle Scholar

Farlow MR. Utilizing combination therapy in the treatment of Alzheimer's disease. Expert Rev Neurother 2004;4(5):799–808.PubMedCrossRefGoogle Scholar

Pietrzik C, Behl C. Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int J Exp Pathol 2005;86(3):173–185.PubMedCrossRefGoogle Scholar

Marlatt MW, Webber KM, Moreira PI, et al. Therapeutic opportunities in Alzheimer disease: one for all or all for one? Curr Med Chem 2005;12(10):1137–1147.PubMedCrossRefGoogle Scholar

Standridge JB. Current status and future promise of pharmacotherapeutic strategies for Alzheimer's disease. J Am Med Dir Assoc 2005;6(3):194–199.PubMedCrossRefGoogle Scholar

Rossom R, Adityanjee, Dysken M. Efficacy and tolerability of memantine in the treatment of dementia. Am J Geriatr Pharmacother 2004;2(4):303–312.PubMedCrossRefGoogle Scholar

Doraiswamy PM. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs 2002;16(12):811–824.PubMedCrossRefGoogle Scholar

Greig NH, Pei XF, Soncrant TT, et al. Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. Med Res Rev 1995;15(1):3–31.PubMedCrossRefGoogle Scholar

Greig NH, De Micheli E, Holloway HW, et al. The experimental Alzheimer drug phenserine: pharmacokinetics and pharmacodynamics in the rat. Acta Neurol Scand 2000;176:74–84.CrossRefGoogle Scholar

Greig NH, Sambamurti K, Yu QS, et al. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimers Res 2005;2:281–291.CrossRefGoogle Scholar

Lahiri D, Chen D, Vivien D, et al. The role of cytokines in the gene expression of amyloid β-protein precursor: identification of a 5′UTR binding nuclear factor and its implications for Alzheimer's disease. J Alzheimer Dis 2003;5:81–90.Google Scholar

Lahiri DK, Farlow MR, Hintz N, et al (2000) Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease. Acta Neurol Scand 2000;176:60–67.CrossRefGoogle Scholar

Lahiri DK, Farlow MR, Sambamurti K. (1998) The secretion of amyloid beta-peptide is inhibited in tacrine-treated human neuroblastoma cells. Mol Brain Res 1998;62:131–140.PubMedCrossRefGoogle Scholar

Lahiri DK, Farlow MR. Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. J Mol Neurosci 1996;7(1):41–49.PubMedCrossRefGoogle Scholar

Yu QS, Greig NH, Holloway HW, Brossi A. Syntheses and anticholinesterase activities of (3aS)-N(1), N(8)-bisnorphenserine(3aS)-N(1), N(8)-bisnorphysostigmine, their antipodal isomers, and other potential metabolites of phenserine. J Med Chem 1998;41:2371–2379.PubMedCrossRefGoogle Scholar

Yu QS, Holloway HW, Utsuki T, et al. Phenserine-based synthesis of novel selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J Med Chem 1999;42:1855–1861.PubMedCrossRefGoogle Scholar

Yu QS, Holloway HW, Flippen-Anderson F, et al. Methyl analogues of the experimental Alzheimer drug, phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. J Med Chem 2001;44:4062–4071.PubMedCrossRefGoogle Scholar

Yu QS, Zhu X, Holloway HW, et al. Anticholinesterase activity of compounds related to geneserine tautomers―N-oxides and 1,2-oxazines. J Med Chem 2002;45:3684–3691.PubMedCrossRefGoogle Scholar

Luo X, Yu QS, Zhan M, et al. Novel anticholinesterases based on the molecular skeletons of furobenzofuran and benzodioxepine. J Med Chem 2005;48(4):986–994.PubMedCrossRefGoogle Scholar

Haroutunian V, Greig NH, Utsuki T, et al. Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Mol Brain Res 1997;46:161–168.PubMedCrossRefGoogle Scholar

Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr 2002;14:77–91.PubMedCrossRefGoogle Scholar

Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc Natl Acad Sci. USA, 2005;102:17213–8.PubMedCrossRefGoogle Scholar

Coelho F, Birks J. Physostigmine for Alzheimer's disease. Cochrane Database Syst Rev 2001;2:CD001499.PubMedGoogle Scholar

Shaw KT, Utsuki T, Rogers J, et al. Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 2001;98(13):7605–7610.PubMedCrossRefGoogle Scholar

Rogers JT, Randall JD, Cahill CM, et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 2002;277(47):45518–45528.PubMedCrossRefGoogle Scholar

Venti A, Giordano T, Eder P, et al. The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5′-untranslated region. Ann N Y Acad Sci. 2004;1035:34–44.Google Scholar

Maloney B, Ge YW, Greig NH, Lahiri DK. Presence of a “CAGA box” in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: implications in Alzheimer's disease. FASEB J 2004;18(11):1288–1290.PubMedGoogle Scholar

Patel N, Spangler E, Greig NH, et al. Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the NMDA receptor. Neuroreport 1998;9:171–176.PubMedCrossRefGoogle Scholar

Greig NH. Drug entry to the brain and its pharmacologic manipulation. In, Handb Exp Pharmacol 1992;103:487–523.Google Scholar

Greig NH, Yu QS, Utsuki T, et al. Optimizing drugs for brain action. In: Koliber D, Lustig S, Shapira S (eds) Blood-Brain Barrier Drug Delivery and Brain Pathology. New York: Kluwer Academic/Plenum, 2002, pp 281–309.Google Scholar

Thal LJ. Therapeutics and mild cognitive impairment: current status and future directions. Alzheimer Dis Assoc Disord 2003;17(suppl 2):S69–S71.Google Scholar

Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res 2003;28(3-4):515–522.PubMedCrossRefGoogle Scholar

Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363(9427):2105–2115.PubMedCrossRefGoogle Scholar

Lopez OL, Becker JT, Saxton J, et al. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 2005;53:83–87.PubMedCrossRefGoogle Scholar

Greig NH, Mattson MP, Perry T, et al. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-α inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci 2004;1035:290–315.PubMedCrossRefGoogle Scholar

Cole GM, Morihara T, Lim GP, et al. NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. Ann N Y Acad Sci 2004;1035:68–84.PubMedCrossRefGoogle Scholar

Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280(7):5892–5901.PubMedCrossRefGoogle Scholar

Hoglund K, Thelen KM, Syversen S, et al. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2005;19(5-6):256–266.PubMedCrossRefGoogle Scholar

Doraiswamy PM, Steffens DC, McQuoid DR. Statin use and hippocampal volumes in elderly subjects at risk for Alzheimer's disease: a pilot observational study. Am J Alzheimers Dis Other Demen 2004;19(5):275–278PubMedCrossRefGoogle Scholar

Ritchie CW, Bush AI, Masters CL. Metal-protein attenuating compounds and Alzheimer's disease. Expert Opin Invest Drugs 2004;13(12):1585–1592.CrossRefGoogle Scholar

Lahiri DK, Sambamurti K, Bennett DA. Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease. Neurobiol Aging 2004;25(5):651–660.PubMedCrossRefGoogle Scholar

Greig NH, Sambamurti K, Yu QS, et al. Butyrylcholinesterase: its selective inhibition and relevance to Alzheimer's disease. In: Giacobini E (ed) Butyrylcholinesterase: Its Function and Inhibition. London: Martin Dunitz, 2003, pp 69–90.Google Scholar

Soreq H, Seidman S. Acetylcholinesterase―new roles for an old actor. Nat Rev Neurosci 2001;2:294–302.PubMedCrossRefGoogle Scholar

Massoulie J. Molecular forms and anchoring of acetylcholinesterase. In: Giacobini E (ed) Cholinesterases and Cholinesterase Inhibitors. London: Martin Dunitz, 2000, pp 81–102.Google Scholar

Soreq H, Gnatt A, Loewenstein Y, Neville LF. Excavations into the active-site gorge of cholinesterases. Trends Biochem Sci 1992;17:353–358.PubMedCrossRefGoogle Scholar

Dvir H, Wong DM, Harel M, et al. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates. Biochemistry 2002;41:2970–2981.PubMedCrossRefGoogle Scholar

Silman I, Millard CB, Ordentlich A, et al. A preliminary comparison of structural models for catalytic intermediates of acetylcholinesterase. Chem Biol Interact 1999;May 14:119–120.Google Scholar

Silman I, Harel M, Axelsen P, et al. Three-dimensional structures of acetylcholinesterase and of its complexes with anticholinesterase agents. Biochem Soc Trans 1994;22:745–749.PubMedGoogle Scholar

Inestrosa NC, Sagal JP, Colombres M. Acetylcholinesterase interaction with Alzheimer amyloid beta. Subcell Biochem 2005;38:299–317.PubMedGoogle Scholar

Nitsch RM, Farber SA, Growdon JH, Wurtman RJ. Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc Natl Acad Sci U S A 1993;90(11):5191–5193.PubMedCrossRefGoogle Scholar

Muller DM, Mendla K, Farber SA, Nitsch RM. Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci 1997;60(13-14):985–991.PubMedCrossRefGoogle Scholar

Buxbaum JD, Greengard P. Regulation of APP processing by intra- and intercellular signals. Ann N Y Acad Sci 1996;777:327–331.PubMedCrossRefGoogle Scholar

Desdouits-Magnen J, Desdouits F, Takeda S, et al. Regulation of secretion of Alzheimer amyloid precursor protein by the mitogen-activated protein kinase cascade. J Neurochem 1998;70(2):524–530.PubMedGoogle Scholar

Utsuki T, Shoaib M, Lahiri DK, et al. Nicotine reduces the secretion of Alzheimer's ß-Amyloid precursor protein containing ß-Amyloid peptide in the rat. J Alzheimers Dis 2002;4:405–415.PubMedGoogle Scholar

Lahiri DK, Utsuki T, Chen D, et al. Nicotine reduces the secretion of Alzheimer's beta-amyloid precursor protein containing beta-amyloid peptide in the rat without altering synaptic proteins. Ann N Y Acad Sci 2002;965:364–372.PubMedCrossRefGoogle Scholar

Yu QS, Luo W, Holloway HW, et al. Racemic N¹-norphenserine and its enantiomers: unpredicted inhibition of acetyl- and butyrylcholinesterase and β-amyloid precursor protein in vitro. Heterocycles 2003;61:529–539.CrossRefGoogle Scholar

Munoz FJ, Aldunate R, Inestrosa NC. Peripheral binding site is involved in the neurotrophic activity of acetylcholinesterase. Neuroreport 1999;10(17):3621–3625.PubMedCrossRefGoogle Scholar